BEACON-HCC: Best evidence and north american consensus on treatment allocation for hepatocellular carcinoma
Expert treatment decisions showed 96.6% concordance with BEACON-HCC recommendations.
The BEACON-HCC treatment allocation framework diverges from prior frameworks by incorporating nuanced clinical features such as degree of intrahepatic tumor burden and vascular invasion, and adverse tumor prognostic markers, to align treatment allocation with tumor biology and therapeutic potential. Key innovations include the incorporation of emerging modalities such as external beam radiation therapy (EBRT), transarterial radioembolization (TARE), and systemic‑locoregional combination therapies. In a pilot exercise, expert treatment decisions showed 96.6% concordance with BEACON‑HCC recommendations and 72.4% concordance with BCLC recommendations.
High concordance demonstrates that the BEACON-HCC framework aligns closely with expert opinion, indicating its potential to improve clinical decision‑making for hepatocellular carcinoma.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Quercetin suppresses the progression of HBV-associated hepatocellular carcinoma by modulating the EGFR signaling pathway
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- Surgical treatment of hepatocellular carcinoma: expert consensus statement
- Loco-regional treatment of hepatocellular carcinoma
- Real‑World Outcomes of Atezolizumab‑Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort